-+ 0.00%
-+ 0.00%
-+ 0.00%
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Share
Listen to the news

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 150 points on Friday.

Shares of Xenon Pharmaceuticals Inc (NASDAQ:XENE) fell sharply in pre-market trading after the company announced a temporary pause in enrollment for new patients in its ongoing psychiatry studies.

The company said it voluntarily paused enrollment in ongoing clinical studies in major depressive disorder and bipolar depression following an analysis of neuropsychiatric adverse events.

Xenon Pharmaceuticals shares tumbled 27.6% to $41.51 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

  • Frontline Plc (NYSE:FRO) fell 6.4% to $50.65 in pre-market trading.
  • Biohaven Ltd (NYSE:BHVN) fell 6.4% to $13.00 in pre-market trading after jumping over 15% on Thursday.
  • Stewards Inc. (NASDAQ:SWRD) declined 4.7% to $2.03 in pre-market trading after jumping around 18% on Thursday.
  • Steel Dynamics Inc (NASDAQ:STLD) dropped 4.5% to $234.42 in pre-market trading. Steel Dynamics said it sees third-quarter EPS of $5.34-$5.38, up from $3.69 in the second quarter and $2.74 in the year-ago period.
  • Array Technologies Inc (NASDAQ:ARRY) declined 4.3% to $4.06 in pre-market trading.
  • EyePoint Inc (NASDAQ:EYPT) fell 4% to $3.83 in pre-market trading after jumping over 15% on Thursday.
  • Nucor Corp (NYSE:NUE) fell 3.1% to $257.00 in pre-market trading. Nucor said it sees third-quarter earnings of $5.55 to $5.65 per diluted share, up from $2.63 per share in the year-ago quarter.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending